New treatment that could prove curative for blood cancer

Hundreds of people with an aggressive type of blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a potentially curative new treatment option on the NHS, with approval of the drug glofitamab.

Around 5,500 people are diagnosed with this type of cancer in England each year which mainly affects men aged 65 and over, with the most common symptom being painless swellings of the glands.